This checker was developed for the Australian veteran population and may not be universally applicable.

The suggested actions and clinical comments are based on available information sources including the Australian Product Information, available at the Australian Register of Therapeutic Goods Website, the Liverpool COVID-19 Interactions Checker, the Ontario COVID-19 Science Advisory Table and the NIH Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and the Concomitant Medication . For some medicines, data on nirmatrelvir plus ritonavir interaction is limited.

Contraindicated (Red) - For these medicines, there is a risk of serious side effects or reduced treatment efficacy. Do not co-administer with nirmatrelvir plus ritonavir.

Attention required (Orange) - There is potential interaction with nirmatrelvir plus ritonavir, and clinical evaluation of current therapy is recommended.

Follow up (Grey) - The potential interaction usually does not require pre-emptive therapy change, but should be monitored over time.

No known interaction (Green) - No interaction between this medicine and nirmatrelvir plus ritonavir is expected.